Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 17/20 | 0.64 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29780388 | 0.86 | VCAM1 (0.73) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL809482 | 0.86 | VCAM1 (0.73) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL10452716 | 0.86 | VCAM1 (0.73) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL27809726 | 0.83 | VCAM1 (0.61) | VCAM1ALDH1A1DNMT1DNMT3A | |
| SCHEMBL12639368 | 0.83 | VCAM1 (0.65) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL11876453 | 0.82 | VCAM1 (0.58) | VCAM1ALDH1A1 | |
| SCHEMBL7536581 | 0.82 | VCAM1 (0.57) | VCAM1ALDH1A1 | |
| SCHEMBL10719874 | 0.81 | VCAM1 (0.63) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL4001670 | 0.81 | VCAM1 (0.64) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27825662 | 0.81 | VCAM1 (0.57) | VCAM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | CYP46A1, TGFB1, NR1H2 | VCAM1 51/4885NPBWR1 1953/4885MCHR1 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.